Exhibit 99.2
MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
THIRD QUARTER
2009
EQUITY INCOME FROM AFFILIATES (millions of dollars)
| 3Q ‘09 | 3Q ‘08 | YTD 2009 | YTD 2008 | |||||||||||||
MERCK / SCHERING-PLOUGH | $ | 391.3 | $ | 400.2 | $ | 1,044.5 | $ | 1,158.2 | ||||||||
ASTRAZENECA LP | 191.4 | 139.1 | 482.6 | 331.6 | ||||||||||||
Other (1) | 105.5 | 126.3 | 334.1 | 350.9 | ||||||||||||
TOTAL | $ | 688.2 | $ | 665.6 | $ | 1,861.2 | $ | 1,840.7 | ||||||||
| (1) | Primarily reflects results for Sanofi Pasteur MSD, Johnson & Johnson°Merck Consumer Pharmaceuticals and Merial Limited (until disposition on September 17, 2009). |
JOINT VENTURE SALES DETAIL (millions of dollars)
All sales reported here are end-market JV sales, presented on a “NET” basis.
Merial(1) | Period from July 1, 2009 until Sept. 17, 2009 | 3Q ‘08 | Period from Jan. 1, 2009 until Sept. 17, 2009 | YTD 2008 | ||||||||||||
FRONTLINE, other fipronil | $ | 197.5 | $ | 253.3 | $ | 783.9 | $ | 901.0 | ||||||||
BIOLOGICALS | 164.4 | 198.0 | 524.5 | 580.9 | ||||||||||||
IVOMEC, HEARTGARD, other avermectins | 91.3 | 128.6 | 341.4 | 415.0 | ||||||||||||
Other Animal Health | 61.0 | 72.1 | 199.7 | 220.8 | ||||||||||||
TOTAL MERIAL SALES | $ | 514.2 | $ | 652.0 | $ | 1,849.5 | $ | 2,117.7 | ||||||||
| (1) | On September 17, 2009, Merck sold its ownership interest in Merial Limited. Sales figures for 2009 are reported until the date of disposition. |
Sanofi Pasteur MSD | 3Q ‘09 | 3Q ‘08 | YTD 2009 | YTD 2008 | ||||||||||||
GARDASIL | $ | 108.1 | $ | 220.1 | $ | 417.1 | $ | 694.1 | ||||||||
FLU VACCINES | 167.1 | 117.2 | 167.1 | 117.2 | ||||||||||||
OTHER VIRAL VACCINES | 26.6 | 28.9 | 78.9 | 80.7 | ||||||||||||
HEPATITIS VACCINES | 10.3 | 19.3 | 34.7 | 56.7 | ||||||||||||
ROTATEQ | 10.7 | 7.9 | 29.5 | 21.2 | ||||||||||||
Other Vaccines | 173.0 | 173.4 | 425.0 | 438.3 | ||||||||||||
TOTAL SANOFI PASTEUR MSD SALES | $ | 495.8 | $ | 566.8 | $ | 1,152.3 | $ | 1,408.2 | ||||||||
Merck / Schering-Plough Collaboration | 3Q ‘09 | 3Q ‘08 | YTD 2009 | YTD 2008 | ||||||||||||
VYTORIN | $ | 514.1 | $ | 567.2 | $ | 1,500.0 | $ | 1,810.5 | ||||||||
ZETIA | 514.5 | 534.3 | 1,507.3 | 1,676.4 | ||||||||||||
TOTAL MERCK / SCHERING-PLOUGH SALES | $ | 1,028.6 | $ | 1,101.5 | $ | 3,007.3 | $ | 3,486.9 | ||||||||
OTHER (INCOME) EXPENSE, NET (millions of dollars)
| 3Q ‘09 | 3Q ‘08 | YTD 2009 | YTD 2008 | |||||||||||||
INTEREST INCOME | $ | (33.4 | ) | $ | (171.3 | ) | $ | (199.6 | ) | $ | (484.2 | ) | ||||
INTEREST EXPENSE | 130.7 | 71.4 | 290.9 | 194.6 | ||||||||||||
EXCHANGE LOSSES (GAINS) | 0.5 | 52.3 | (3.0 | ) | 73.6 | |||||||||||
Other, net(1) | (2,888.9 | ) | 78.2 | (2,943.0 | ) | (2,075.3 | ) | |||||||||
TOTAL | $ | (2,791.1 | ) | $ | 30.6 | $ | (2,854.7 | ) | $ | (2,291.3 | ) | |||||
| (1) | Other, net in the third quarter and first nine months of 2009 primarily reflects a $2.8 billion gain on the sale of the Company’s ownership interest in Merial Limited. Other, net in the first nine months of 2008 primarily reflects a $2.2 billion gain on distribution from AstraZeneca LP. |
Exhibit 99.2
MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
THIRD QUARTER
2009
NET PRODUCT SALES DETAIL (millions of dollars)
| 3Q ‘09 vs. 3Q ‘08 | ||||||||||||
| TOTAL | TOTAL | U.S. | U.S. | Foreign | Foreign | |||||||
PRODUCT | % CHG | $ | % CHG | $ | % CHG | $ | ||||||
COZAAR / HYZAAR | -3% | 861 | 3% | 322 | -6% | 539 | ||||||
JANUVIA | 30% | 491 | 19% | 354 | 68% | 137 | ||||||
JANUMET | 72% | 173 | 42% | 122 | * | 51 | ||||||
SINGULAIR | 5% | 1,085 | 5% | 729 | 6% | 356 | ||||||
Vaccines: | ||||||||||||
GARDASIL | -22% | 311 | -20% | 220 | -27% | 91 | ||||||
ROTATEQ | -6% | 127 | -9% | 113 | 36% | 13 | ||||||
ZOSTAVAX | * | 84 | * | 84 | N/A | — | ||||||
OTHER VIRAL VACCINES(1) | 7% | 462 | 9% | 440 | -18% | 22 | ||||||
HEPATITIS VACCINES(2) | 26% | 46 | 63% | 42 | -62% | 4 | ||||||
OTHER VACCINES(3) | 71% | 138 | * | 99 | 17% | 39 | ||||||
Other Reported Products: | ||||||||||||
ARCOXIA | -7% | 90 | N/A | — | -7% | 90 | ||||||
CANCIDAS | 5% | 155 | -26% | 18 | 11% | 137 | ||||||
COSOPT / TRUSOPT | -41% | 123 | -92% | 7 | -5% | 116 | ||||||
CRIXIVAN / STOCRIN | -28% | 49 | -26% | 2 | -28% | 47 | ||||||
EMEND | 20% | 82 | 17% | 51 | 26% | 31 | ||||||
FOSAMAX | -22% | 276 | -59% | 39 | -8% | 237 | ||||||
INVANZ | 3% | 73 | 5% | 39 | — | 34 | ||||||
ISENTRESS | 84% | 197 | 68% | 95 | * | 102 | ||||||
MAXALT | 6% | 144 | 8% | 100 | 2% | 44 | ||||||
PRIMAXIN | -10% | 168 | 3% | 33 | -13% | 135 | ||||||
PROPECIA | 1% | 109 | -5% | 37 | 4% | 72 | ||||||
PROSCAR | -17% | 67 | -52% | 2 | -15% | 66 | ||||||
TIMOPTIC / TIMOPTIC XE | -8% | 28 | * | — | -2% | 28 | ||||||
VASOTEC / VASERETIC | -12% | 73 | N/A | — | -12% | 73 | ||||||
ZOCOR | -10% | 141 | 3% | 17 | -12% | 124 | ||||||
ZOLINZA | 24% | 5 | 15% | 4 | * | 1 | ||||||
* 100% or over
N/A - Not Applicable
(1) - Includes ProQuad, M-M-R II and Varivax.
(2) - Includes Recombivax and Vaqta
(3) - Includes Pneumovax, Comvax and Pedvaxhib
TOTAL SALES: VOLUME, PRICE, EXCHANGE
| 3Q ‘09 | % CHG | VOL | PX | FX | ||||||||
TOTAL PHARMACEUTICAL SALES | $ | 6,050 | 2 | % | 2 | 2 | -3 | |||||
U.S. ($ MM) | 3,455 | 4 | % | -1 | 4 | N/A | ||||||
Foreign ($ MM) | 2,595 | 0 | % | 6 | -1 | -6 | ||||||
Exhibit 99.2
MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
SEPTEMBER YEAR-TO-DATE
2009
NET PRODUCT SALES DETAIL (millions of dollars)
| SEPTEMBER YTD ‘09 vs. SEPTEMBER YTD ‘08 | |||||||||||||||
PRODUCT | TOTAL % CHG | TOTAL $ | U.S. % CHG | U.S. $ | Foreign % CHG | Foreign $ | |||||||||
COZAAR / HYZAAR | -3 | % | 2,606 | 3 | % | 958 | -6 | % | 1,648 | ||||||
JANUVIA | 39 | % | 1,364 | 29 | % | 1,014 | 77 | % | 350 | ||||||
JANUMET | 97 | % | 456 | 61 | % | 336 | * | 120 | |||||||
SINGULAIR | 6 | % | 3,400 | 6 | % | 2,234 | 6 | % | 1,165 | ||||||
Vaccines: | |||||||||||||||
GARDASIL | -25 | % | 841 | -29 | % | 584 | -12 | % | 258 | ||||||
ROTATEQ | -23 | % | 387 | -27 | % | 345 | 29 | % | 42 | ||||||
ZOSTAVAX | 34 | % | 202 | 34 | % | 202 | N/A | — | |||||||
OTHER VIRAL VACCINES(1) | 6 | % | 1,036 | 9 | % | 977 | -24 | % | 59 | ||||||
HEPATITIS VACCINES(2) | 1 | % | 109 | 20 | % | 95 | -52 | % | 14 | ||||||
OTHER VACCINES(3) | 11 | % | 246 | 45 | % | 158 | -22 | % | 88 | ||||||
Other Reported Products: | |||||||||||||||
ARCOXIA | -12 | % | 260 | N/A | — | -12 | % | 260 | |||||||
CANCIDAS | -3 | % | 442 | -31 | % | 55 | 3 | % | 388 | ||||||
COSOPT / TRUSOPT | -41 | % | 370 | -87 | % | 33 | -10 | % | 337 | ||||||
CRIXIVAN / STOCRIN | -31 | % | 154 | -21 | % | 8 | -31 | % | 146 | ||||||
EMEND | 18 | % | 228 | 18 | % | 147 | 19 | % | 81 | ||||||
FOSAMAX | -34 | % | 815 | -71 | % | 122 | -15 | % | 693 | ||||||
INVANZ | 4 | % | 205 | 10 | % | 109 | -2 | % | 96 | ||||||
ISENTRESS | * | 518 | 96 | % | 257 | * | 260 | ||||||||
MAXALT | 8 | % | 418 | 13 | % | 291 | -3 | % | 127 | ||||||
PRIMAXIN | -17 | % | 493 | -23 | % | 95 | -15 | % | 398 | ||||||
PROPECIA | -1 | % | 318 | -4 | % | 109 | 1 | % | 208 | ||||||
PROSCAR | -13 | % | 219 | -55 | % | 4 | -12 | % | 214 | ||||||
TIMOPTIC / TIMOPTIC XE | -9 | % | 82 | -91 | % | — | -4 | % | 82 | ||||||
VASOTEC / VASERETIC | -17 | % | 226 | N/A | — | -17 | % | 226 | |||||||
ZOCOR | -18 | % | 419 | -46 | % | 35 | -14 | % | 384 | ||||||
ZOLINZA | 27 | % | 13 | 24 | % | 12 | 57 | % | 1 | ||||||
* 100% or over
N/A - Not Applicable
(1) - Includes ProQuad, M-M-R II and Varivax.
(2) - Includes Recombivax and Vaqta
(3) - Includes Pneumovax, Comvax and Pedvaxhib
TOTAL SALES: VOLUME, PRICE, EXCHANGE
| SEP YTD ‘09 | % CHG | VOL | PX | FX | ||||||||
TOTAL PHARMACEUTICAL SALES | $ | 17,335 | -3 | % | -1 | 2 | -4 | |||||
U.S. ($ MM) | 9,662 | -3 | % | -8 | 4 | N/A | ||||||
Foreign ($ MM) | 7,673 | -2 | % | 8 | -2 | -8 | ||||||
